Crispr Stock Analysis

CRSP
 Stock
  

USD 53.73  1.06  1.93%   

Crispr Therapeutics price decline over the last few months could raise concerns from insiders as the firm is trading at a share price of 53.73 on 157,600 in volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in November. However, diversifying your holdings with Crispr Therapeutics AG or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.92. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Crispr Therapeutics partners.
Continue to Trending Equities.
  
The Crispr Therapeutics stock analysis report makes it easy to digest most publicly released information about Crispr Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Crispr Stock analysis module also helps to analyze the Crispr Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Crispr Stock Analysis Notes

About 69.0% of the company shares are held by institutions such as insurance companies. The book value of Crispr Therapeutics was currently reported as 24.97. The company had not issued any dividends in recent years. Crispr Therapeutics had 333333:100 split on the 19th of July 2016. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Crispr Therapeutics AG please contact Rodger Novak at 41 41 561 32 77 or go to https://www.crisprtx.com.

Crispr Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Crispr Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Crispr Therapeutics AG or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Crispr Therapeutics generated a negative expected return over the last 90 days
Crispr Therapeutics has high historical volatility and very poor performance
About 69.0% of the company shares are held by institutions such as insurance companies
Latest headline from news.google.com: Propulsion of Thalassemia Pipeline as Novel and Extensive 25 Therapies Likely to Enter in the Treatment Domain DelveInsight - Yahoo Finance

Crispr Therapeutics Upcoming and Recent Events

Earnings reports are used by Crispr Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Crispr Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report15th of February 2022
Next Financial Report26th of April 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End15th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Crispr Largest EPS Surprises

Earnings surprises can significantly impact Crispr Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-05-11
2017-03-31-0.61-0.540.0711 
2019-07-29
2019-06-30-0.9-1.01-0.1112 
2020-10-28
2020-09-30-1.18-1.32-0.1411 
View All Earnings Estimates

Crispr Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Crispr Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Crispr Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Crispr Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
8th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
21st of June 2022
Financial Statements and Exhibits. Other Events
View
13th of June 2022
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
View
16th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure
View
12th of May 2022
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
9th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
15th of February 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
14th of February 2022
Unclassified Corporate Event
View

Crispr Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 4.18 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Crispr Therapeutics's market, we take the total number of its shares issued and multiply it by Crispr Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Crispr Profitablity

Crispr Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Crispr Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Crispr Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Crispr Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Crispr Therapeutics' profitability requires more research than a typical breakdown of Crispr Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets 0.14  0.16 
Return on Average Equity 0.16  0.17 
Return on Invested Capital 0.26  0.28 
Return on Sales 0.41  0.45 

Management Efficiency

The entity has return on total asset (ROA) of (0.166) % which means that it has lost $0.166 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.3048) %, meaning that it created substantial loss on money invested by shareholders. Crispr Therapeutics management efficiency ratios could be used to measure how well crispr therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 1st of December 2022, Return on Average Assets is likely to grow to 0.16. Also, Return on Average Equity is likely to grow to 0.17. As of 1st of December 2022, Total Liabilities is likely to grow to about 380.2 M. Also, Current Liabilities is likely to grow to about 129.3 M
Last ReportedProjected for 2022
Book Value per Share 31.59  34.09 
Enterprise Value over EBIT 13.00  14.03 
Enterprise Value over EBITDA 12.52  13.50 
Price to Book Value 2.42  3.01 
Tangible Assets Book Value per Share 36.23  30.69 
Enterprise ValueB4.5 B
Tangible Asset Value2.8 BB

Technical Drivers

As of the 1st of December, Crispr Therapeutics shows the mean deviation of 3.01, and Risk Adjusted Performance of (0.07). Crispr Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Crispr Therapeutics AG, which can be compared to its rivals. Please confirm Crispr Therapeutics information ratio, as well as the relationship between the potential upside and kurtosis to decide if Crispr Therapeutics is priced correctly, providing market reflects its regular price of 53.73 per share. Given that Crispr Therapeutics has jensen alpha of (0.31), we suggest you to validate Crispr Therapeutics AG's prevailing market performance to make sure the company can sustain itself at a future point.

Crispr Therapeutics Price Movement Analysis

The output start index for this execution was three with a total number of output elements of fifty-eight. Crispr Therapeutics Triple Exponential Moving Average indicator shows smoothing effect of Crispr Therapeutics price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.
.

Crispr Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Crispr Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Crispr Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Crispr Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Thomas Woiwode over a week ago via Macroaxis 
Purchase by Thomas Woiwode of 95596 shares of CRISPR Therapeutics
Samarth Kulkarni over a month ago via Macroaxis 
Exercise or conversion by Samarth Kulkarni of 25000 shares of CRISPR Therapeutics subject to Rule 16b-3
Morrow Phuong Khanh over a month ago via Macroaxis 
Acquisition by Morrow Phuong Khanh of 9380 shares of CRISPR Therapeutics subject to Rule 16b-3
Samarth Kulkarni over two months ago via Macroaxis 
Exercise or conversion by Samarth Kulkarni of 25000 shares of CRISPR Therapeutics subject to Rule 16b-3
Samarth Kulkarni over three months ago via Macroaxis 
Exercise or conversion by Samarth Kulkarni of 25000 shares of CRISPR Therapeutics subject to Rule 16b-3
Samarth Kulkarni over three months ago via Macroaxis 
Exercise or conversion by Samarth Kulkarni of 16667 shares of CRISPR Therapeutics subject to Rule 16b-3
Samarth Kulkarni over three months ago via Macroaxis 
Exercise or conversion by Samarth Kulkarni of 25000 shares of CRISPR Therapeutics subject to Rule 16b-3
Fleming Harold Edward over three months ago via Macroaxis 
Acquisition by Fleming Harold Edward of 12000 shares of CRISPR Therapeutics subject to Rule 16b-3
Morrow Phuong Khanh over six months ago via Macroaxis 
Acquisition by Morrow Phuong Khanh of 90000 shares of CRISPR Therapeutics subject to Rule 16b-3
Klein Lawrence Otto over six months ago via Macroaxis 
Exercise or conversion by Klein Lawrence Otto of 3000 shares of CRISPR Therapeutics subject to Rule 16b-3
Smith Brendan over six months ago via Macroaxis 
Acquisition by Smith Brendan of 15300 shares of CRISPR Therapeutics subject to Rule 16b-3
Samarth Kulkarni over six months ago via Macroaxis 
Exercise or conversion by Samarth Kulkarni of 17750 shares of CRISPR Therapeutics subject to Rule 16b-3

Crispr Therapeutics Predictive Daily Indicators

Crispr Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Crispr Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Crispr Therapeutics Forecast Models

Crispr Therapeutics time-series forecasting models is one of many Crispr Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Crispr Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Crispr Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Crispr Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Crispr shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Crispr Therapeutics. By using and applying Crispr Stock analysis, traders can create a robust methodology for identifying Crispr entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin 0.50  0.54 
Gross Margin 0.90  0.89 
Profit Margin 0.47  0.51 

Current Crispr Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Crispr analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Crispr analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
160.69Buy13Odds
Crispr Therapeutics AG current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Crispr analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Crispr stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Crispr Therapeutics, talking to its executives and customers, or listening to Crispr conference calls.
Crispr Analyst Advice Details

Crispr Stock Analysis Indicators

Crispr Therapeutics AG stock analysis indicators help investors evaluate how Crispr Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Crispr Therapeutics shares will generate the highest return on investment. By understating and applying Crispr Therapeutics stock analysis, traders can identify Crispr Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow1185468000.00
Logo U R LimglogosUSCRSP.png
Common Stock Shares Outstanding65949672.00
Total Stockholder Equity2399460000.00
DescriptionCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 pl
Total Cashflows From Investing Activities-1035430000.00
Tax Provision1870000.00
Property Plant And Equipment Net312035000.00
Retained Earnings-195915000.00
Cash And Short Term Investments2379129000.00
Retained Earnings Total Equity-195915000.00
Cash923031000.00
CodeCRSP
Accounts Payable14816000.00
Net Debt-698001000.00
50 Day M A57.6158
Total Current Liabilities119883000.00
Currency CodeUSD
Other Operating Expenses541435000.00
Non Current Assets Total334364000.00
Forward Price Earnings23.3645
Common Stock Total Equity2391000.00
Non Currrent Assets Other22204000.00
Continue to Trending Equities. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for analysis

When running Crispr Therapeutics price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.2 B
Quarterly Revenue Growth YOY
(0.89) 
Return On Assets
(0.17) 
Return On Equity
(0.30) 
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Crispr Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.